Virtual screening of approved drugs against purine nucleoside phosphorylase of Schistosoma mansoni

Schistosomiasis is an endemic neglected tropical disease caused by trematodes of the genus Schistosoma. Purine nucleoside phosphorylase (PNP) of purine salvage pathway is essential for recovery of nucleosides in Schistosoma species. Schistosoma mansoni PNP (SmPNP) is well-explored drug target for schistosomiasis. The currently available drugs have adverse effects such as abdominal discomfort, nausea, drowsiness and pyrexia. Hence, there is a need for new compounds exhibiting anti-schistosomal activity with minimal or no side effects. In the present study, virtual screening of approved drugs from Drug Bank was compared against Schistosoma mansoni and human PNPs. Among the approved drugs, 15 molecules were selected based on the interaction scores, out of which 11 drugs interacted with SmPNP and the remaining four interacted with human PNP.

[1]  J. Irwin,et al.  ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .

[2]  M. Tanner,et al.  Advances with the Chinese anthelminthic drug tribendimidine in clinical trials and laboratory investigations. , 2013, Acta tropica.

[3]  Glaucius Oliva,et al.  Purine nucleoside phosphorylase from Schistosoma mansoni in complex with ribose-1-phosphate , 2010, Journal of synchrotron radiation.

[4]  C. Dissous,et al.  Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective? , 2011, Trends in parasitology.

[5]  A. Cámara-Artigas,et al.  Crystallographic and thermodynamic analysis of the binding of S-octylglutathione to the Tyr 7 to Phe mutant of glutathione S-transferase from Schistosoma japonicum. , 2005, Biochemistry.

[6]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[7]  P. Fallon,et al.  Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. , 1994, The American journal of tropical medicine and hygiene.

[8]  V. Scaria,et al.  Cheminformatics Models for Inhibitors of Schistosoma mansoni Thioredoxin Glutathione Reductase , 2014, TheScientificWorldJournal.

[9]  Bruno J. Neves,et al.  In Silico Repositioning-Chemogenomics Strategy Identifies New Drugs with Potential Activity against Multiple Life Stages of Schistosoma mansoni , 2015, PLoS neglected tropical diseases.

[10]  J. Utzinger,et al.  Drugs for treating urinary schistosomiasis. , 2008, The Cochrane database of systematic reviews.

[11]  D. Dyer,et al.  Aldose reductase from Schistosoma japonicum: crystallization and structure-based inhibitor screening for discovering antischistosomal lead compounds , 2013, Parasites & Vectors.

[12]  G. Oliva,et al.  Adenosine binding to low-molecular-weight purine nucleoside phosphorylase: the structural basis for recognition based on its complex with the enzyme from Schistosoma mansoni. , 2010, Acta crystallographica. Section D, Biological crystallography.

[13]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[14]  B. S. Sekhon.  repositioning drugs and biologics: retargeting old/existing drugs for potential new therapeutic applications , 2013 .

[15]  Ghyslain Mombo-Ngoma,et al.  Efficacy of mefloquine intermittent preventive treatment in pregnancy against Schistosoma haematobium infection in Gabon: a nested randomized controlled assessor-blinded clinical trial. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[17]  S. Xiao,et al.  In vitro and in vivo studies of the effect of artemether on Schistosoma mansoni , 1989, Antimicrobial Agents and Chemotherapy.

[18]  K. Warren,et al.  Control of schistosomiasis: report of a workshop. , 1979, The American journal of tropical medicine and hygiene.

[19]  G. Coles,et al.  Drug resistance in schistosomiasis: a review. , 1987, Memorias do Instituto Oswaldo Cruz.

[20]  Marcelo Santos Castilho,et al.  Discovery of New Inhibitors of Schistosoma mansoni PNP by Pharmacophore-Based Virtual Screening , 2010, J. Chem. Inf. Model..

[21]  Eric Martz,et al.  Protein Data Bank (PDB) , 2004 .

[22]  G. Franco,et al.  Structures for the potential drug target purine nucleoside phosphorylase from Schistosoma mansoni causal agent of schistosomiasis. , 2005, Journal of molecular biology.

[23]  G. Schneider,et al.  Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. , 2001, Journal of combinatorial chemistry.

[24]  Masaud Shah,et al.  Molecular docking study of P4-Benzoxaborolesubstituted ligands as inhibitors of HCV NS3/4A protease , 2013, Bioinformation.

[25]  J. Keiser,et al.  In vitro and in vivo antischistosomal activity of ferroquine derivatives , 2014, Parasites & Vectors.

[26]  O. Toure,et al.  Efficacy of Artesunate + Sulfamethoxypyrazine/Pyrimethamine versus Praziquantel in the Treatment of Schistosoma haematobium in Children , 2009, PloS one.

[27]  D. Dyer,et al.  3-Oxoacyl-ACP Reductase from Schistosoma japonicum: Integrated In Silico-In Vitro Strategy for Discovering Antischistosomal Lead Compounds , 2013, PloS one.

[28]  A. Henglein,et al.  The New Insecticide O,O-Dimethyl 2,2,2-Trichloro-1-hydroxyethylphosphonate , 1955 .

[29]  J. Utzinger,et al.  Antimalarials in the treatment of schistosomiasis. , 2012, Current pharmaceutical design.

[30]  Roman A. Laskowski,et al.  LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..

[31]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[32]  G. Oliva,et al.  Structural basis for selective inhibition of purine nucleoside phosphorylase from Schistosoma mansoni: kinetic and structural studies. , 2010, Bioorganic & medicinal chemistry.

[33]  A. Lebrun,et al.  A new approach to helminthiasis control: the use of an organophosphorous compound. , 1962, The American journal of tropical medicine and hygiene.

[34]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[35]  Gail M Williams,et al.  Schistosomiasis elimination: lessons from the past guide the future. , 2010, The Lancet. Infectious diseases.

[36]  J. Keiser,et al.  Repurposing drugs for the treatment and control of helminth infections , 2014, International journal for parasitology. Drugs and drug resistance.

[37]  S. Al-Waheeb,et al.  Disseminated peritoneal Schistosoma japonicum: a case report and review of the pathological manifestations of the helminth , 2009, Annals of Saudi medicine.

[38]  D. L. Klayman,et al.  Qinghaosu (artemisinin): an antimalarial drug from China , 1985 .

[39]  M. F. Useh.  Control of Schistosomiasis , 2012 .

[40]  Christophe Romier,et al.  Discovery of Inhibitors of Schistosoma mansoni HDAC8 by Combining Homology Modeling, Virtual Screening, and in Vitro Validation , 2014, J. Chem. Inf. Model..

[41]  V. Berdini,et al.  Crystal structure of Schistosoma purine nucleoside phosphorylase complexed with a novel monocyclic inhibitor. , 2009, Acta tropica.